

Under the Auspices of




AMERICAN SOCIETY OF HYPERTENSION



Asian
Society Of
Continuing
Medical
Education

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update



October 11 -12, 2014,

Ramoji Film City, Hyderabad, India

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update

“2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update”

Date: October 11th – 12th, 2014

Venue: Ramoji Film City, Hyderabad, India

Total No. Of Delegates: 350

“2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update” was conducted by Asian Society of Continuing Medical Education in collaboration with American Society of Hypertension.

The sole objective of the CME was to update the Cardiologists, endocrinologists, internists and family physicians about new techniques and guidelines in management of the following aspects of hypertension, dyslipidemias and diabetes under the auspices of the American Society of Hypertension.

The CME was of two days divided under different headings such as

Day 1 -

India Risk Summit and Best of ASH Symposium October 11, 2014

Controversies and Consensus in Guidelines

Moderator: Dr. Matthew Weir and Dr. Dayasagar Rao

Mini - Symposium on Hypertension

Moderator: Dr. Sanjay Rajagopalan and Dr. Atul Ingale

Risk Factor Symposium

Moderator: Dr. Michael Farkouh and Dr. A. Ramachandran

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update

Day 2 –

**Special Symposium on Reducing Risk in the High Risk Type II Diabetic
October 12, 2014**

Optimizing Management of the Type II Diabetic

Moderator: Dr. Sanjay Rajagopalan and Dr. Atul Ingale

Panelist: (Both Day 1 and Day 2)

Dr. Atul Ingale, MD. FRCP

Fellow American Board of Nephrology (USA), MGM Group of Hospitals & Medical College, India

Faculties: (Both Day 1 and Day 2)

- 1. Dr. Eric Peterson, MD, M.P.H**
Duke University, Durham, NC
- 2. Dr. Michael Farkouh, MD, FRCP.**
University of Toronto, Canada
- 3. Dr. Sanjay Rajagopalan, M.B.B.S, FACC, FAHA**
University of Maryland, Baltimore
- 4. Dr. Mattew Weir, MD.**
University of Maryland, Baltimore
- 5. Dr. Allan Sniderman, MD., FRCP**
McGill University, Montreal, Canada

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update

6. **Dr. Allan Gradman**, MD, FACC, FASH
Temple University School of Medicine, Pittsburgh, Pennsylvania
7. **Prof. Dr. A. Ramachandran** , M.D., Ph.D., D.Sc., FRCP.(Lond), FRCP (Edin)
President, India Diabetes Research Foundation, Chennai, India
8. **Dr. Dayasagar Rao** , MD, DM (Card) FRCP (Canada), MRCP (Edin)
Krishna Institute of Medical Science, Hyderabad, Andhra Pradesh, India

LECTURES: (Both Day 1 and Day 2)

- Recommendations for treating hypertension: what are the right goals and purposes?
- Clinical Guidelines and Clinical Reasoning-Limitations of Evidence Based Evidence
- A Perspective on the 2013 US Guidelines for Hypertension: Where Does the so Called “Evidence Based Approach” Fall Short?
- 2013 ACC/AHA Cholesterol Treatment Guidelines
- Current Guidelines for Treatment of Type II Diabetes: Are We Pushing the Limits of the Evidence Base?
- How Does the Clinician Integrate Guidelines into Practice: A Case Based Approach in Hypertension, Lipids and Type II Diabetes
- Epidemiology of Hypertension in India: Insights from PURE
- My patient presents with “uncontrolled hypertension”: how to rule out pseudo-resistant hypertension causes. A Case Based Discussion
- Approach to the True Resistant hypertensive and Treatment Approaches
- What Should the Goal Blood Pressure and Ideal Agent(s) be in the Post-Stroke Patient?
- Management of Hypertension in the CKD Patient
- Community Based Intervention for Blood Pressure: What Works and what does not?

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update

- What should be our target for LDL lowering therapy and why?
- Newer Treatment Strategies: Mipomersen, Lomitapide and PCSK9
- Approach and Management of Triglyceride Based Disorders
- Optimizing Anti-Platelet Management in the Type II Diabetic with CAD: Focus on Newer Therapies
- Revascularization in Type II Diabetes: Challenges and Evidence from Randomized Clinical Trials
- Glycemic Control for Macrovascular Disease in Type II Diabetes: Evidence and Insights from Recent Trials
- Multivessel PCI in the Type II Diabetic: Who Are Appropriate Candidates and Should There be Country Specific Guidelines?
- Hypertension Management in High Risk Type II Diabetes with CKD: Insights from Recent Trials with a Focus on Albuminuria. A Case Based Discussion
- Statin Induced Diabetes: A Case Based Approach

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update



Dr. Eric Peterson

MD, M.P.H

Duke University, Durham, NC

Dr. Eric Peterson talked on topics:

1. Recommendations for treating hypertension: what are the right goals and purposes?
2. Community Based Intervention for Blood Pressure: What Works and what does not?
3. Optimizing Anti-Platelet Management in the Type II Diabetic with CAD: Focus on Newer Therapies

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update



Dr. Allan Sniderman,
MD., FRCP
McGill University, Montreal

Dr. Allan Sniderman spoke on topics:

1. Clinical Guidelines and Clinical Reasoning-Limitations of Evidence Based Evidence
2. What should be our target for LDL lowering therapy and why?
3. Statin Induced Diabetes: A Case Based Approach
4. Approach and Management of Triglyceride Based Disorders

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update



Dr. Allan Gradman,
MD, FACC, FASH
Temple University School of
Medicine, Pittsburgh, Pennsylvania

Dr. Allan Gradman talked on topics:

1. A Perspective on the 2013 US Guidelines for Hypertension: Where Does the so Called “Evidence Based Approach” Fall Short?
2. What Should the Goal Blood Pressure and Ideal Agent(s) be in the Post-Stroke Patient?

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update



Dr. Sanjay Rajagopalan,
M.B.B.S, FACC, FAHA
University of Maryland, Baltimore

Dr. Sanjay Rajagopalan delivered a lecture on

1. 2013 ACC/AHA Cholesterol Treatment Guidelines
2. Newer Treatment Strategies: Mipomersen, Lomitapide and PCSK9
3. How Does the Clinician Integrate Guidelines into Practice: A Case Based Approach in Hypertension, Lipids and Type II Diabetes
4. Glycemic Control for Macrovascular Disease in Type II Diabetes: Evidence and Insights from Recent Trials

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update



Prof. Dr. A. Ramachandran,
M.D., Ph.D., D.Sc., FRCP.(Lond)
President, India Diabetes Research
Foundation, Chennai, India

Prof. Dr. A. Ramachandran talked on topics:

1. Current Guidelines for Treatment of Type II Diabetes: Are We Pushing the Limits of the Evidence Base?
2. How Does the Clinician Integrate Guidelines into Practice: A Case Based Approach in Hypertension, Lipids and Type II Diabetes

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update



Dr. Matthew Weir,
MD.
University of Maryland, Baltimore

Dr. Matthew Weir gave lecture on topics:

1. How Does the Clinician Integrate Guidelines into Practice: A Case Based Approach in Hypertension, Lipids and Type II Diabetes
2. Approach to the True Resistant hypertensive and Treatment Approaches
3. Management of Hypertension in the CKD Patient
4. Hypertension Management in High Risk Type II Diabetes with CKD: Insights from Recent Trials with a Focus on Albuminuria. A Case Based Discussion

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update



Dr. Dayasagar Rao,
MD, DM (Card) FRCP (Canada), MRCP
Krishna Institute of Medical Science,
Hyderabad, Andhra Pradesh, India

Dr. Dayasagar Rao delivered a lectured on –

1. Epidemiology of Hypertension in India: Insights from PURE
2. My patient presents with uncontrolled hypertension": how to rule out pseudo-resistant hypertension causes. A Case Based Discussion

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update



Dr. Michael Farkouh,
MD, FRCP.
University of Toronto, Canada

Dr. Michael Farkouh gave a lecture on –

1. Revascularization in Type II Diabetes: Challenges and Evidence from Randomized Clinical Trials
2. Multivessel PCI in the Type II Diabetic: Who Are Appropriate Candidates and Should There be Country Specific Guidelines?

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update

FEEDBACKS FROM DELEGATES:

1. Highlights genetic, congenital analysis in hypertensive among children 2 adolescences
2. Young Hypertension & Endocrine Hypertension
3. Topics on patient empowering of disease in clinics , Topics on Life style modification
4. Cardiac Rehabilitation
5. Management of various types of arrhythmias
6. PIH & Hypertension management in young
7. Rheumatic Heart Disease & Cardiomyopathies
8. Management of DM should be added
9. Rheumatic valvular Disease , Polypill concept
10. Heart Failure , Atrial Fibrillation , Current aspect & relevance to India
11. Hypertension Variability
12. Stress on Pharmacotherapy , Complication profiles & Management
13. Acute Coronary syndrome & Hear Failure
14. Management of arrhythmia
15. Adverse Cardiac events in poorly controlled Diabetes Mellitus & hence its primary prevention & management
16. Heart Failure , Arrhythmia with conduction disturbance
17. Absorbable stents and their future usage in interventional cardiology
18. Arrhythmias and their effective management

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update

19. 2D Echo & Recent advances in Echocardiography to rule out cardiac disease at earliest
20. More Clinical Topics
21. Slides of Dr. Sniderman were entertaining & impressive
22. Role of primary PCI - DM type 2
23. There should be more clinical discussion , Less epidemiological talks
24. Surgical intervention if any case of dilated cardiomyopathy (DCM)
25. New OHAs & CV Risk
26. Condense Course
27. Compensated Hypertension by some patient without symptoms
28. Endothelial dysfunction in post-myocardial infarction tissue
29. ECG Interpretation, Thyroid dysfunction
30. Role of Alcohol & Tobacco in HT & DM
31. Rheumatic Heart Disease
32. Relationship of arrhythmia with hypertension and management
33. Hyponatremia with heart, CAD, Cirrhosis of liver with Hepatorenal syndrome , CAD,SVT with COPD & CLD
34. Management of CHF with Hepatorenal syndrome
35. Heart Failure, Arrhythmias
36. Methodology of research - How to proceed in our clinical practice - India scenario

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update

Comments/Suggestions from Delegates:

- At least 25% of time for entertainment and City visit
- Keep it Brief
- The schedule should be arranged in extended period
- More concentration on current scenario rather than too many studies
- Require more of similar programmes
- Keep it continue further
- The duration on day 1 was too much, The sequence was not coherent ,
The session could have been interactive after each session or theme ,e.g.
Disease based, Association based , End organ based & Need to follow
Adult learning principles
- Keep it up
- Should have been more on clinical content
- Good keep it up
- It is wonderful events and highly informative
- Over all it's a nice informative programme , Hope to see more such
programme
- Good Conference
- I Congratulate Sir A. Ramachandran ,He is excellent, confident &
associative
- CME should be in morning , Afternoon and Evening should be for rest &
entertainment

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update

- Keep it up
- Invite clinical cases from physicians of India ,give them to present and then discussion by International faculties
- Recent advances topic should be included
- General education on how to read a paper, understand the numbers and evaluate the evidence by myself instead of relying in Expert explaining
- Good one ,Excellent
- Not so many lectures - So tightly packed
- Very useful and concepts are clearly discussed
- CME/Annual Membership
- Question & answer session with buzzer and bell
- The presentation by Dr. Sniderman & Dr. Farkouh were through provoking and enhanced our understanding of lipidology & cardiology in respect to Diabetic
- Continue with full passion
- Too Lengthy
- This type of CME at least twice yearly , would be more beneficial for me
- We need regular update program time to time
- Thanks m Very good education
- Session could be more interactive, Practical aspects need more emphasis
- Tea should be provided continuously as after travelling in night, post lunch session, most of audience were sleeping, answers to case studies by audience

2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update

PHOTOGRAPHS



Registration Desk



Panel Discussion



2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update

Few Photographs of Faculty and Delegates Discussion



2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update

Delegates Listening to the Faculty



2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update

FELICITATION OF FACULTIES



2nd Annual India Cardiovascular Risk Summit in Conjunction with Best of ASH 2014 Update



ASH Team



Delegates